Overview

The Effects of Cilostazol Dexborneol on Microcirculation Dysfunction and Thrombo-inflammation in Patients With Acute Ischemic Stroke After Reperfusion Therapy

Status:
Not yet recruiting

Trial end date:
2023-07-01

Target enrollment:

Participant gender:

Summary

This study aims to evaluate the efficacy of Y-6 sublingual tablets in improving microcirculation dysfunction and reducing thrombo-inflammation in patients who had AIS caused by LVO and received reperfusion therapy. Moreover, we expect to evaluate the safety of using Y-6 sublingual tablet in such study population.

Phase:

Phase 2

Details

Lead Sponsor:

Beijing Tiantan Hospital

Collaborator:

NeuroDawn Pharmaceutical Co., Ltd.